Hemospray in the treatment of upper gastrointestinal hemorrhage in patients on antithrombotic therapy

Patients on antithrombotic therapy (ATT) have the highest risk of ongoing bleeding and mortality. Hemospray (Cook Medical, Winston-Salem, North Carolina, USA) is a novel hemostatic agent for the treatment of upper gastrointestinal bleeding (UGIB). Initial reports on its use appear promising in terms of initial hemostasis and rebleeding rates. It is unknown whether this also pertains to patients on ATT. The aim of the current study therefore was to evaluate the efficacy of Hemospray in the treatment of UGIB in patients taking ATTs. A total of 16 unselected consecutive patients with UGIB who were treated with Hemospray were analyzed (eight taking ATT for various indications and eight not on ATT). Initial hemostasis was achieved after Hemospray application in 5 /8 patients on ATT (63 %) and in all eight patients not on therapy (P = 0.20). Rebleeding rates were similar in both groups. These preliminary data on the use of Hemospray in the management of UGIB are promising in both patients with and without ATT; however, caution should be exercised for its use in patients on ATT with spurting arterial bleeding.

• References

• 1 Hearnshaw SA, Logan RF, Palmer KR et al. Outcomes following early red blood cell transfusion in acute upper gastrointestinal bleeding. Aliment Pharmacol Ther 2010; 32: 215-224
• 2 Theocharis GJ, Thomopoulos KC, Sakellaropoulos G et al. Changing trends in the epidemiology and clinical outcome of acute upper gastrointestinal bleeding in a defined geographical area in Greece. J Clin Gastroenterol 2008; 42: 128-133
• 3 Sung JJ. Chapter 3: Gastrointestinal bleeding: antiplatelets and anticoagulants. In: Sung JJ, Kuipers EJ, Barkun AN, eds. Gastrointestinal bleeding. 2nd. edn. London: Wiley-Blackwell; 2012
• 4 Shingina A, Barkun AN, Razzaghi A et al. Systematic review: the presenting international normalised ratio (INR) as a predictor of outcome in patients with upper nonvariceal gastrointestinal bleeding. Aliment Pharmacol Ther 2011; 33: 1010-1018
• 5 Sung JJ, Luo D, Wu JC et al. Early clinical experience of the safety and effectiveness of Hemospray in achieving hemostasis in patients with acute peptic ulcer bleeding. Endoscopy 2011; 43: 291-295
• 6 Chen YI, Barkun AN, Soulellis C et al. Use of the endoscopically applied hemostatic powder TC-325 in cancer-related upper GI hemorrhage: preliminary experience (with video). Gastrointest Endosc 2012; 75: 1278-1281
• 7 Smith LA, Stanley AJ, Bergman JJ et al. Hemospray for non-variceal upper gastrointestinal bleeding: results of the SEAL dataset (survey to evaluate the application of Hemospray in the luminal tract). Abstract presented at Digestive Disease Week; 2012 May 20–22; San Diego, California. Gastrointest Endosc 2012; 75: AB133-AB134
• 8 Park CH, Min SW, Sohn YH et al. A prospective, randomized trial of endoscopic band ligation vs. epinephrine injection for actively bleeding Mallory–Weiss syndrome. Gastrointest Endosc 2004; 60: 22-27
• 9 Lo CC, Hsu PI, Lo GH et al. Comparison of hemostatic efficacy for epinephrine injection alone and injection combined with hemoclip therapy in treating high-risk bleeding ulcers. Gastrointest Endosc 2006; 63: 767-773
• 10 Gross PL, Weitz JI. New antithrombotic drugs. Clin Pharmacol Ther 2009; 86: 139-146